Alector, Inc

Add to watchlist
€20.0
Last updated:07/30/2021
0Z2: F
Alector, Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, A… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company profile
CEO
Dr. Arnon Rosenthal
Market capitalization
Small (1.77B)